Prolongation of Survival of Nude Mice Bearing Human Colon Cancer
| Autor: | Philip M. Wanek, David M. Hyams, J. David Beatty, Jose M. Esteban, Barbara G. Beatty |
|---|---|
| Rok vydání: | 1989 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Mice Nude Monoclonal antibody Cell Line Mice Antigen medicine Animals Yttrium Radioisotopes Dosing Mice Inbred BALB C business.industry Carcinoma Therapeutic effect Antibodies Monoclonal Carcinoembryonic Antigen Surgery Human colon cancer Cell culture Colonic Neoplasms Toxicity Female Anti-Carcinoembryonic Antigen Antibody business |
| Zdroj: | Archives of Surgery. 124:175 |
| ISSN: | 0004-0010 |
| DOI: | 10.1001/archsurg.1989.01410020045007 |
| Popis: | • Nude mice bearing diffuse intraperitoneal carcinomatosis of the human colon cancer cell line LS174T were treated with an anti–carcinoembryonic antigen monoclonal antibody (MAB) that was labeled with yttrium 90 ( 90 Y-ZCE025). Control animals were either untreated or treated with nonspecific 99 Y-MAB ( 90 Y-96.5c). The median survival (MS) for untreated animals was 26 days. The MS for specific and nonspecific therapy that consisted of 120 μCi of 90 Y-MAB was 69 and 34 days, respectively. No significant improvement in the MS was observed with a second 120-μCi administration of 90 Y-MAB given two weeks later. A decreased MS was observed with 80 μCi of 90 Y-MAB given every four days for three cycles. In each category, specific therapy had a significant advantage over nonspecific therapy in increased effectiveness and decreased toxicity. The 90 Y-ZCE025 therapy gave an increased life span of almost 200%. The therapeutic effects with different dosing regimens have important implications for treatment planning. ( Arch Surg 1989;124:175-179) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|